Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD

Oncotarget. 2018 Nov 6;9(87):35721-35722. doi: 10.18632/oncotarget.26291.
No abstract available

Keywords: GvHD; IFNGR; IL6R; JAK1/JAK2; baricitinib.

Publication types

  • Editorial